Belén Garijo

Chair of the Executive Board and Chief Executive Officer, Merck

Belén Garijo is Vice Chair of the Executive Board of Merck and Deputy Chief Executive Officer. She was appointed to the Executive Board in 2015. She is responsible for the Healthcare business sector and since 2013, she has acted as President and CEO of the Biopharma business, where she started in 2011 as Chief Operating Officer. In September 2017, Belén Garijo also assumed Executive Board responsibility for Group Human Resources.

Before joining Merck, Belén Garijo served as the Senior Vice President Global Operations Europe at Sanofi-Aventis, where she was also a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003, she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer.

Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA.

最新記事

COVID-19

ジェンダ不平等拡大する介護在り方浮き彫り新型コロナウイルス

新型コロナウイルス大流行により介護必要増し予期大きな課題提起れる介護認識評価性差による偏向減らいくこと緊急高まっます特にリソ限られ患者多く入院できない状況おい新型コロナウイルス患者その家族とって緩和ケアおよび終末ケア必要高いものなる考えられます

2020年05月18日

メルマガの登録

グローバル・アジェンダのウィークリー・アップデート

© 2021 World Economic Forum

プライバシーポリシーと利用規約